Modulating the pulmonary circulation: An update

Current Opinion in Anaesthesiology

Volumn 16, Issue 1, 2003, Pages 59-64

  Dembinski, Rolf ^a   Rossaint, Rolf ^b   Kuhlen, Ralf ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b NONE

Author keywords

Acute respiratory distress syndrome; Cardiac surgery; Cardiopulmonary bypass; Heart transplantation; Hypoxic pulmonary vasoconstriction; Lung transplantation; One lung ventilation; Pulmonary circulation; Pulmonary hypertension; Volatile anaesthetics

Indexed keywords

ACETYLCHOLINE; ALMITRINE DIMESILATE; BRADYKININ; ENFLURANE; HALOTHANE; INHALATION ANESTHETIC AGENT; ISOFLURANE; MIDAZOLAM; NITRIC OXIDE; SEVOFLURANE; SILDENAFIL;

ANESTHESIA; CARDIOPULMONARY BYPASS; DRUG ABSORPTION; DRUG MECHANISM; EXTRACORPOREAL CIRCULATION; GENERAL ANESTHESIA; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; LUNG CIRCULATION; LUNG DISEASE; LUNG TRANSPLANTATION; LUNG VASOCONSTRICTION; LUNG VENTILATION; PATHOPHYSIOLOGY; PATIENT SELECTION; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; VASODILATATION;

EID: 0037322738     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200302000-00009     Document Type: Review

References (39)

1. Murray P, Fehr D, Chen B, et al. Differential effects of general anesthesia on cGMP-mediated pulmonary vasodilation. J Appl Physiol Heart Circ Physiol 1992; 73:721-727.
2. Gambone L, Fujiwara Y, Murray P. Endothelium-dependent pulmonary vasodilation in conscious dogs is selectively attenuated during isoflurane anesthesia. Am J Physiol 1997; 272:H290-H298.
3. Seki S, Sato K, Nkayama M, Murray P. Halothane and enflurane attenuate pulmonary vasodilation mediated by ATP-sensitive potassium channels compared to the conscious state. Anesthesiology 1997; 86:923-935.
4. ATP channel activation and circulatory hypotension in chronically-instrumented dogs. Anesthesiology 1999; 90:799-811.
5. Lennon P, Murray P. Isoflurane and the pulmonary vascular pressure-flow relation at baseline and during sympathetic α- and β-adrenoreceptor activation in chronically instrumented dogs. Anesthesiology 1995; 82:723-733.
6. Sato K, Seki S, Murray PA. Effects of halothane and enflurane anesthesia on sympathetic beta-adrenoreceptor-mediated pulmonary vasodilation in chronically instrumented dogs. Anesthesiology 2002; 97:478-487. An interesting study investigating new details of the effects of volatile anaesthetics in general anaesthesia.
7. Eisenkraft J. Effects of anaesthetics on the pulmonary circulation. Brit J Anaesth 1990; 65:63-78.
8. Liu R, Ueda M, Okazaki N, Ishibe Y. Role of potassium channels in isoflurane- and sevoflurane-induced attenuation of hypoxic pulmonary vasoconstriction in isolated perfused rabbit lungs. Anesthesiology 2001; 95:939-946. A nice experimental study adding new information to the mechanisms by which volatile anaesthetics may attenuate hypoxic pulmonary vasoconstriction.
9. Loeckinger A, Keller C, Lindner KH, Kleinsasser A. Pulmonary gas exchange in coronary artery surgery patients during sevoflurane and isoflurane anesthesia. Anesth Analg 2002; 94:1107-1112. A very important study with clinical implications for the use of inhalational anaesthetics adding clinical results to the experimental data.
10. Hall R, Stafford Smith M, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic and pharmacological considerations. Anesth Analg 1997; 85:766-782.
11. Cugno M, Nussberger J, Biglioli P, et al. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest 2001; 120:1776-1782. A very good clinical trial evaluating the important role of the lung in the context of the inflammatory response after cardiopulmonary bypass.
12. Kirshbom P, Page S, Jacobs M, et al. Cardiopulmonary bypass and circulatory arrest increase endothelin-1 production and receptor expression in the lung. J Thorac Cardiovasc Surg 1997; 113:777-783.
13. Joffs C, Walker CA, Hendrick JW, et al. Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2001; 122:365-370. An interesting experimental study offering a new therapeutic strategy for the treatment of pulmonary hypertension after cardiopulmonary bypass.
14. Viaro F, Dalio MB, Evora PR. Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: should methylene blue be the treatment of choice? Chest 2002; 122:1061-1066. A very interesting and clinically important review of four clinical trials performed to investigate the side effects of protamin when neutralizing heparin after cardiopulmonary bypass.
15. Angdin M, Settergren G, Vaage J. Better preserved pulmonary endothelium-dependent vasodilation with off-pump coronary surgery. Scand Cardiovasc J 2001; 35:264-269. A clinically relevant study which should encourage further clinical investigations to be performed in the field of off-pump cardiac surgery.
16. Maxey TS, Smith CD, Kern JA, et al. Beneficial effects of inhaled nitric oxide in adult cardiac surgical patients. Ann Thorac Surg 2002; 73:529-532. Although retrospective, this study may help to further determine the potential role of nitric oxide for the treatment of selected patients in clinical practice.
17. Solina AR, Ginsberg SH, Papp D, et al. Response to nitric oxide during adult cardiac surgery. J Invest Surg 2002; 15:5-14. A well performed clinical study, investigating the effects of nitric oxide in patients undergoing cardiac surgery in correlation to the amount of preoperative pulmonary hypertension.
18. Haraldsson SA, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001; 93:1439-1445. A very interesting clinical study, adding new therapeutic options to the conventional treatment of postoperative pulmonary hypertension after cardiac surgery.
19. Rocca G, Passariello M, Coccia C, et al. Inhaled nitric oxide administration during one-lung ventilation in patients undergoing thoracic surgery. J Cardiothorac Vasc Anesth 2001; 15:218-223. A good clinical study, evaluating different effects of inhaled nitric oxide with regard to the amount of pulmonary hypertension and hypoxia in patients undergoing one-lung ventilation.
20. Moutafis M, Dalibon N, Liu N, et al. The effects of intravenous almitrine on oxygenation and hemodynamics during one-lung ventilation. Anesth Analg 2002; 94:830-834. A clinical trial performed to investigate the modulation of the hypoxic pulmonary vasoconstriction by almitrine. This study is of clinical importance, because a certain dose of almitrine is demonstrated to be effective without major side effects.
21. Tuxen DV. Permissive hypercapnic ventilation. Am J Respir Crit Care Med 1994; 150:870-874.
22. Sticher J, Muller M, Scholz S, et al. Controlled hypercapnia during one-lung ventilation in patients undergoing pulmonary resection. Acta Anaesthesiol Scand 2001; 45:842-847. Although of limited value due to its short-term character, this clinical study demonstrates that lung protective ventilation may also be performed safely in one-lung ventilation.
23. Schwarzkopf K, Schreiber T, Bauer R, et al. The effects of increasing concentrations of isoflurane and desflurane on pulmonary perfusion and systemic oxygenation during one-lung ventilation in pigs. Anesth Analg 2001; 93:1434-1438. An interesting experimental study with clinical implications for the use of volatile anaesthetics in one-lung ventilation.
24. McQuitty CK. Con: inhaled nitric oxide should not be used routinely in patients undergoing lung transplantation. J Cardiothorac Vasc Anesth 2001; 15:790-792. See annotation for following reference.
25. Lang JD Jr, Lell W. Pro: inhaled nitric oxide should be used routinely in patients undergoing lung transplantation. J Cardiothorac Vasc Anesth 2001; 15:785-789. Excellent well written articles providing a good overview of the actual discussion.
26. Delgado JF, Gomez-Sanchez MA, Saenz dlC, et al. Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. J Heart Lung Transplant 2001; 20:942-948. An important retrospective study evaluating even mild pulmonary hypertension as an important risk factor for early postoperative mortality after heart transplantation.
27. Ardehali A, Hughes K, Sadeghi A, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001; 72:638-641. Further results of another good clinical study to determine the potential role of nitric oxide for the treatment of selected patients in clinical practice.
28. Langer F, Wendler O, Wilhelm W. Treatment of a case of acute right heart failure by inhalation of iloprost, a long-acting prostacyclin analogue. Eur J Anaesthesiol 2001; 18:770-773. An interesting case report which should encourage the investigation of iloprost for the treatment of acute right heart failure in clinical studies.
29. Zink M, Gombotz H, Wasler A, et al. Urapidil reduces elevated pulmonary vascular resistance in patients before heart transplantation. J Heart Lung Transplant 2002; 21:347-353. A well performed study with important clinical implications.
30. 2 sensors, and controversies. News Physiol Sci 2002; 17:131-137. An excellent review providing a very interesting overview of the actual theories for the mechanism of hypoxic pulmonary vasoconstriction.
31. Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80:151-155.
32. Blumberg FC, Riegger GA, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest 2002; 121:1566-1571. An interesting clinical trial which presented new details of the benefits of iloprost in pulmonary hypertension.
33. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329. Certainly the most important study with regard to the effects of iloprost in pulmonary hypertension because this study demonstrated an improvement of relevant outcome parameters.
34. Michelakis E, Tymchak W, Lien D. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105:2398-2403. New data about the use of phosphodiesterase inhibitors in pulmonary hypertension.
35. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136:515-522. A reasonable study evaluating the promising combination of iloprost and phosphodiesterase inhibitors in pulmonary hypertension.
36. Schermuly RT, Weissmann N, Enke B, et al. Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. Am J Respir Cell Mol Biol 2001; 25:219-225. A new therapeutic option is investigated in this experimental study, with promising results.
37. Hubler M, Souders JE, Shade ED, et al. Effects of perfluorohexane vapor on relative blood flow distribution in an animal model of surfactant-depleted lung injury. Crit Care Med 2002; 30:422-427. See annotation for following reference.
38. Hubler M, Souders JE, Shade ED, et al. Effects of vaporized perfluorocarbon on pulmonary blood flow and ventilation/perfusion distribution in a model of acute respiratory distress syndrome. Anesthesiology 2001; 95:1414-1421. Both are very interesting studies with regard to the fact that the beneficial effects of vaporized perfluorocarbons in ARDS are not completely understood until today.
39. Jeng MJ, Kou YR, Sheu CC, et al. Effects of partial liquid ventilation with FC-77 on acute lung injury in newborn piglets. Pediatr Pulmonol 2002; 33:12-21. A nice experimental trial confirming the results of older studies but with a different perfluorocarbon.